Gilead Sciences, Inc. (GILD)
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.
Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Gilead Sciences, Inc. (NASDAQ:GILD ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ET Company Participants Daniel P. O'Day - Chairman & CEO Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Great.
Gilead shares fall after FDA places clinical hold on HIV treatment trials
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) dropped up to 4% on Tuesday following an announcement that the US Food and Drug Administration (FDA) has placed clinical holds on studies involving two of the company's investigational HIV drugs. The FDA's clinical hold affects trials of GS-1720, an integrase strand transfer inhibitor, and GS-4182, a capsid inhibitor.
Gilead Sciences, Inc. (GILD) Jefferies Global Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) Jefferies Global Healthcare Conference June 4, 2025 11:05 PM ET Company Participants Cindy Perettie - Executive Vice President of Kite Dietmar P. Berger - Chief Medical Officer Conference Call Participants Michael Jonathan Yee - Jefferies LLC, Research Division Michael Jonathan Yee Good morning, everyone.
Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?
GILD stock jumps 21.1% YTD as HIV dominance, lenacapavir progress, and liver drug approval offset oncology pressures. However, we recommend investors remain on the sidelines at current levels.
Focus: Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty
Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the Trump Administration's pullback in aid spending.
Gilead Sciences, Inc. (GILD) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) Bernstein Annual Strategic Decisions Conference May 29, 2025 2:30 PM ET Company Participants Dan O'Day - Chairman and Chief Executive Officer Conference Call Participants Courtney Breen - Bernstein Courtney Breen All right. Wonderful.
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead Sciences' Best Days May Be Ahead - Here's Why
Despite a sharp decline in sales of COVID-19 blockbuster Veklury, Gilead Sciences once again beat consensus revenue and EPS forecasts. The drugs whose performance impressed me greatly in Q1 2025 and which played a key role in maintaining Gilead's EBIT margin above 38% are Biktarvy, Livdelzi, and Yescarta. Meanwhile, the sales dynamics of its oncology franchise left me with mixed feelings, including due to the increasing pressure from more effective CAR T-cell therapies, bispecific antibodies, and ADCs.
GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer
Gileads Trodelvy shows significant improvement in PFS in phase III ASCENT-03 trial for first-line metastatic TNBC, reinforcing potential as backbone therapy.
Gilead Sciences, Inc. (GILD) RBC Capital Markets Global Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) RBC Capital Markets Global Healthcare Conference May 21, 2025 11:30 AM ET Company Participants Cindy Perettie - Executive Vice President of Kite Conference Call Participants Brian Abrahams - RBC Capital Markets Brian Abrahams Represented by their Executive Vice President of Kite, Cindy Perettie, who is in charge of running their CAR-T franchise. So Cindy, thanks so much for joining us.
